

12th Residential Course on Clinical Pharmacology of Antiretrovirals

Turin, 18-20 January 2017

Starhotels Majestic
corso Vittorio Emanuele II 54
Turin





12th Residential Course on Clinical Pharmacology of Antiretrovirals

Turin, 18-20 January 2017

COURSE DIRECTOR

Prof. G. Di Perri

Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Italy

SCIENTIFIC SECRETARIAT

Prof. S. Bonora

Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Italy

Phone: + 39 011 43933860/43933980, Fax: +39 011 4393996

E-mail: stefano.bonora@unito.it

Organizing Secretariat and CME Provider

HealthData Consulting S.r.l.

Via Morghen, 27 Turin - Italy

Phone +39 011 0267950 - Fax +39 011 0267954

E-mail: segreteria@hdcons.it



COURSE RATIONALE

Rapid advances in HIV and HCV disease management require the ongoing attention of healthcare professionals involved in HIV and HCV medicine. This course will address the implications of new PK/PD information on strategies for clinical management. Information will be presented through a mix of didactic lectures and clinically relevant cases developed by an expert faculty of clinicians and researchers.

LEARNING OBJECTIVES

Participants will be taught on learning goals:

- Recognize the role of PK/PD parameters for the management of HIV and HCV infections.
- Focus on recent developments regarding PK variability of antivirals and its association with specific tissue drug penetration and clearance.
- Describe the challenges of HIV and HCV treatment as it relates to cure and selection of drug resistance.
- Develop strategies to modify or changes on HIV and HCV treatment regimens based on individual patient response.
- Devise a plan to manage drug interactions and adverse effects of HIV and HCV treatments and optimize treatment responses.
- Present real and typical clinical scenarios, discuss findings and management in the light of current PK/PD data and clinical practices guidelines.

TARGET AUDIENCE AND CME CREDITS

The course is designed for healthcare professionals who are actively involved in the medical care of people with HIV and HCV infection.

Provider HealthData Consulting s.r.l. (n.546) has assigned **15 CME credits** according to Italian Health Ministry's criteria. CME credits will only be awarded to Italian participants who attend the entire course. These categories of health professionals are eligible for CME credit assignment: physicians, hospital pharmacists and biologists.

FACULTY

C. Alcantarini, Department of Infectious Diseases, University of Turin, Italy.

M. Andreoni, Department of Infectious Diseases, University "Tor Vergata", Rome, Italy

A. Antinori, Department of Infectious Diseases, IRCCS "Lazzaro Spallanzani", Rome Italy.

D. Back, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.

S. Baghani, Division of Infection and Immunity, University College London, UK.

M. Boffito, St Stephen's AIDS Trust, Chelsea and Westminster Hospital, London, UK.

S. Bonora, Department of Infectious Diseases, University of Turin, Italy.

A. Calcagno, Department of Infectious Diseases, University of Turin, Italy.

- D. Cattaneo**, Clinical Pharmacology Unit, "Luigi Sacco" Hospital, Milan, Italy.
- F. Ceccherini Silberstein**, Virology Unit, University "Tor Vergata", Rome, Italy.
- P. Cinque**, Infectious Diseases Unit, Fondazione Centro S. Raffaele Monte Tabor - H.S. Raffaele, Milan, Italy.
- A. Colbers**, Radboud University Medical Center, Nijmegen, The Netherlands.
- A. D'Avolio**, Department of Infectious Diseases, University of Turin, Italy.
- G. Di Perri**, Department of Infectious Diseases, University of Turin, Italy.
- C. V. Fletcher**, Departments of Pharmacy Practice and Division of Infectious Diseases, Department of Internal Medicine at the University of Nebraska Medical Center, USA.
- C. Flexner**, Division of Clinical Pharmacology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- M. Galli**, Department of Infectious Diseases, University of Milan, Italy.
- R. Garraffo**, Pharmacology Laboratory, CHU Pasteur, Nice France.
- V. Ghisetti**, Microbiology and Virology Laboratory, Amedeo di Savoia Hospital, Turin, Italy.
- A. Hill**, Pharmacology Research Laboratories, University of Liverpool, UK.
- S. Khoo**, Department of Pharmacology & Therapeutics, University of Liverpool, UK.
- M. Kurowski**, Department of Immunodeficiency Diseases, Ludwig Maximilians University, Berlin, Germany.
- M. Lamorde**, Research Department, Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
- S. Letendre**, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
- L. Marinaro**, Department of Infectious Diseases, University of Turin, Italy.
- C. Marzolini**, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.
- C. Montrucchio**, Department of Infectious Diseases, University of Turin, Italy.
- G. Nunnari**, Institute of Infectious Diseases, University of Messina, Italy.
- A. Owen**, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
- N. Pagani**, Department of Infectious Diseases, University of Turin, Italy.
- C. F. Perno**, Virology Unit, University "Tor Vergata", Rome, Italy.
- M. Puoti**, Infectious Diseases Unit, "Niguarda Ca' Granda" Hospital, Milan, Italy.
- M. Rizzetto**, Department of Gastroenterology, University of Turin, Italy.
- G.M. Saracco**, Department of Gastroenterology, University of Turin, Italy.
- M. Siccardi**, Department of Pharmacology & Therapeutics, University of Liverpool, UK.

18th JANUARY, AFTERNOON SESSION

14:15 Welcome lunch and introduction (**G. Di Perri**)

SESSION I - CLINICAL PHARMACOLOGY OF HAART (Chair: M. Galli, M. Kurowski)

14:30 Clinical pharmacology of integrase inhibitors (**M. Boffito**)

15:00 Booster and boosted in the same pill: pharmacological considerations (**S. Bonora**)

15:30 N(t)RTIs: the evolving scenario (**G. Di Perri**)

16:00 Plenary discussion

16:15 Coffee break

16:30 PK variability of antiretrovirals in the clinical setting: which lesson for clinicians? (**D. Cattaneo**)

17:00 Clinical notes: TDM of antiretrovirals in 2017 (**Chair G. Di Perri**)

· - why? (**S. Bonora**)

· - when? (**C. Alcantarini, C. Montrucchio**)

· - how? (**A. D'Avolio**)

18:00 Closing Day 1 Remarks

19th JANUARY, MORNING SESSION

SESSION I - LOOKING FORWARD NEW STANDARDS (Chair: G. Di Perri, S. Khoo)

09:00 The pipeline: long-acting agents and new drugs (**C. Flexner**)

09:30 Nanoformulations of antivirals (**A. Owen**)

10:00 Role of clinical pharmacology in developing countries (**M. Lamorde**)

10:30 Plenary discussion

10:45 Coffee break

SESSION II - DRUG-DRUG INTERACTIONS: HIV VS HCV (Chair: C. Flexner, R. Garraffo)

11:00 Drug-drug interactions in the HIV-positive aging patient (**C. Marzolini**)

11:30 Clinical notes: a new wave of HIV drug-drug interactions (**N. Pagani**)

12:00 Drug drug interactions of Hep-C drugs: data gaps and perspectives (**S. Bonora**)

12:30 New tools to predict and study DDIs (**M. Siccardi**)

13:00 Plenary discussion

13:10 Lunch

19th JANUARY, AFTERNOON SESSION

SESSION III - HCV TREATMENT: OPEN QUESTIONS (Chair: D. Back, M. Rizzetto, G.M. Saracco)

- 14:00 Who are the difficult-to-treat HCV patients nowadays? **(S. Baghani)**
- 14:30 Which role for virologist in DAAs era? **(F. Ceccherini Silberstein)**
- 15:00 Which opportunities for HCV generics? **(A. Hill)**
- 15:30 Plenary discussion
- 15:45 Coffee break
- 16:00 How severe liver disease affect PK of Hep-C drugs? **(G. Di Perri)**
- 16:30 Beyond HCV cure: which reversibility of liver damage? **(M. Puoti)**
- 17:00 Clinical notes: Management of HIV/HCV co-infected patient in real life **(L. Marinaro)**
- 17:30 Plenary discussion
- 17:45 Closing Day 2 Remarks

20th JANUARY, MORNING SESSION

SESSION I - THE HIDDEN WARS (Chair: M. Andreoni, V. Ghisetti, G. Nunnari)

- 09:00 Pharmacokinetics and pharmacodynamics of antiretrovirals in lymphatic and gut tissues **(C. Fletcher)**
- 09:30 PK of antiretrovirals in pregnancy and therapeutic consequences **(A. Colbers)**
- 10:00 Shortening anti-HCV therapy: to what extent? **(C.F. Perno)**
- 10:30 Plenary discussion
- 10:45 Coffee break

SESSION II- CNS AND HIV/HCV (Chair: A. Antinori)

- 11:00 Neurocognitive impairment in HCV chronic infection **(S. Letendre)**
- 11:30 Neuroefficacy vs neurotoxicity of ARVs **(A. Calcagno)**
- 12:00 Clinical notes: management of HAART in patients with HAND **(P. Cinque)**
- 12:30 Plenary discussion
- 12:45 Key learnings 2017 **(G. Di Perri)**
- 13:15 CME test


Please, note that this programme may be subject to alteration and the organizers reserve the right to do so without giving prior notice. The current programme is available at www.fcarvturin.it

COURSE LOCATION and HOTEL ACCOMODATION

Starhotels Majestic

corso Vittorio Emanuele II 54, Torino

Tel +39 011 539153 - Fax +39 011 534963



REGISTRATION INCLUDES

- Admission to all course sessions
- Name tag
- Satchel
- Free onsite wireless
- Catering as per below

Please see what meals are included with your registration below:

DAY	BREAKFAST	MORNING BREAK	LUNCH	AFTERNOON BREAK	DINNER
Wednesday 18 th January	Not included	Not included	Starhotels* Majestic	Starhotels Majestic	Starhotels Majestic
Thursday 19 th January	Not included	Starhotels Majestic	Starhotels Majestic	Starhotels Majestic	Social Dinner
Friday 20 th January	Not included	Starhotels Majestic	Not included**	Not included	Not included

- * Welcome lunch
- ** Light refreshment

A Social Dinner will be offered to the Course's attendees.

Social Dinner is free of charge for participants, but is essential to confirm your presence.

In confirming your participation, let us know if you require a vegetarian meal, or if you have any food intolerance or allergies.





Diamond Sponsor



Gold Sponsor



Silver Sponsor

